Yang Shun-Fa, Hsieh Yih-Shou, Lue Ko-Huang, Chu Shu-Chen, Chang I-Chang, Lu Ko-Hsiu
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
Clin Biochem. 2008 Jan;41(1-2):109-16. doi: 10.1016/j.clinbiochem.2007.10.011. Epub 2007 Oct 26.
The purpose of this study was to examine the ex vivo effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the expression of urokinase-type plasminogen activator (u-PA), PA inhibitor-1 (PAI-1) and gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] in the early knee osteoarthritis (OA) of humans.
Samples of articular cartilage, meniscus and synovium of OA patients were obtained and cultured ex vivo in the presence or absence of NSAIDs (diclofenac sodium, nimesulide, celecoxib, valdecoxib, rofecoxib and etoricoxib).
Gelatin zymography showed that all NSAIDs generally decreased MMP-2 secretion in chondral, meniscal and synovial cultures as well as MMP-9 production in meniscal and synovial cultures. ELISA showed the inhibitions of u-PA secretion in chondral cultures by diclofenac and rofecoxib as well as in chondral and synovial cultures by nimesulide, celecoxib and etoricoxib at 48 h. On PAI-1 secretion, rofecoxib in synovial cultures and diclofenac, nimesulide, celecoxib and etoricoxib in chondral and synovial cultures had significantly suppressive effects at 48 h.
This study clearly demonstrates that NSAIDs can down-regulate the PA/plasmin system and gelatinases expression during the early stage of knee OA, thereby possibly affect the structural progression of the disease. This inhibition seems to be independent selection of COX-1 and COX-2.
本研究旨在探讨非甾体抗炎药(NSAIDs)对人早期膝关节骨关节炎(OA)中尿激酶型纤溶酶原激活剂(u-PA)、PA抑制剂-1(PAI-1)和明胶酶[基质金属蛋白酶(MMP)-2和MMP-9]表达的体外影响。
获取OA患者的关节软骨、半月板和滑膜样本,在有或无NSAIDs(双氯芬酸钠、尼美舒利、塞来昔布、伐地昔布、罗非昔布和依托考昔)存在的情况下进行体外培养。
明胶酶谱分析显示,所有NSAIDs通常都会降低软骨、半月板和滑膜培养物中MMP-2的分泌,以及半月板和滑膜培养物中MMP-9的产生。酶联免疫吸附测定(ELISA)显示,双氯芬酸和罗非昔布在48小时时抑制软骨培养物中u-PA的分泌,尼美舒利、塞来昔布和依托考昔在48小时时抑制软骨和滑膜培养物中u-PA的分泌。关于PAI-1的分泌,罗非昔布在滑膜培养物中以及双氯芬酸、尼美舒利、塞来昔布和依托考昔在软骨和滑膜培养物中在48小时时有显著的抑制作用。
本研究清楚地表明,NSAIDs在膝关节OA早期可下调PA/纤溶酶系统和明胶酶的表达,从而可能影响疾病的结构进展。这种抑制作用似乎与COX-1和COX-2的选择无关。